Mucormycosis is a fungal infection primarily affecting immunocompromised or diabetic patients. Its presentation ranges from rhino-orbito-cerebral infections to disseminated mucormycosis with angi invasion. We present a patient who developed a bowel obstruction one month after bone marrow transplant and was diagnosed with Rhizopus arrhizus diverticulitis despite antifungal therapy since transplantation. She underwent surgical removal with immediate fungal resurgence, declined further invasive intervention and was discharged on palliative isavuconazole. Seven months later she is alive with fungal containment.

1. Introduction

Mucormycosis is a rare but serious fungal infection caused by environmentally ubiquitous molds. While it is classically associated with infections of the head, sinuses, orbits and cerebrum, it can affect any part of the body and may be found in the wounds of trauma patients. Infection occurs primarily in immunocompromised and/or diabetic patients [1]. Mucormycosis frequently presents with nonspecific symptoms which may lead to delayed diagnosis and treatment resulting in higher mortality [2]. Endorsed clinical management guidance is limited to the 2013 European Society for Clinical Microbiology, Infectious Diseases (ESCMID) guidelines, and the cited level of evidence is frequently limited to retrospective reviews, pre-clinical animal studies and expert opinion [3,4]. We present an uncommon presentation of mucormycosis and to date its first description of gastrointestinal mucormycosis described with effective salvage isavuconazole.

2. Case

We report a sixty-two year old female with myelodysplastic syndrome that converted to acute myeloid leukemia. After initiation of induction chemotherapy with Vyxeos, she developed neutropenic fever with enteritis for which she underwent sigmoidoscopy on cycle 1 day 35 of Vyxeos which showed diverticulosis (Image 1). Biopsy revealed no fungal elements and minimal inflammation. She was readmitted approximately one month later for haploidentical stem cell transplantation (HSCT). Prophylactic posaconazole started on day +5 post HSCT. Her hospital course was prolonged due to delayed engraftment with ongoing neutropenia. Four weeks post-transplant she started experiencing abdominal pain and decreased stool output on day +26. Abdominal computed tomography (CT) demonstrated a 4.9 cm peri-rectal abscess on day +30 (Image 2). Cytology of the abscess aspirate revealed aseptate fungal hyphae concerning for mucormycosis (Image 3). (1,3)-β-D-glucan and galactomannan assays were negative. Her absolute neutrophil count had begun to increase up to 900 and she had been taking prophylactic posaconazole prior to HSCT. CT imaging of the sinuses, head and chest were obtained and revealed no other foci of infection. Liposomal amphotericin B at 5mg/kg/day intravenously was started on day +30 with cessation of posaconazole on day +30. Additionally, micafungin 100mg intravenously daily was initiated on day +34.

Fungal isolate from the fungal culture was sent to the University of Texas Health Science Center at San Antonio Fungus Testing Laboratory for species identification. For molecular identification, portions of the culture were suspended in Buffer G2 (Qiagen, Valencia, CA) followed by lysing using a bead beater instrument (Precellys Evolution, Bertin Instruments, Rockville, MD). Proteinase K was added, incubation occurred at 56°C, and the DNA was extracted using an EZ1 DNA tissue kit with a BioRobot EZ1 instrument (Qiagen). The internal transcribed spacer region (ITS) and D1/D2 rRNA gene were then amplified by polymerase chase reaction using previously described primers [5–7]. The PCR products were sequenced, assembled, and analyzed using Sequencer software version 5.4.6 (Gene Codes, Ann Arbor, MI), and the sequences were queried in GenBank using the BLASTn algorithm at the
NCBI website (www.ncbi.nlm.nih.gov). The ITS sequence demonstrated 100% identity to *Rhizopus arrhizus* (GenBank Accession No. AY213684; base pair match 570/570), and the D1/D2 sequence also showed 100% identity to *Rhizopus arrhizus* (GenBank Accession No. AY213624; base pair match 636/636). Further barcode analysis of the ITS sequence demonstrated that the isolate was *Rhizopus arrhizus* var. *arrhizus* [8].

The patient underwent a proctosigmoidectomy with colostomy to remove the fungal abscess on day +33. The post-operative diagnosis was fungal diverticulitis (Image 4). However, six days (day +39) following surgery she had return of fevers and abdominal pain. Repeat abdominal CT showed recurrence of the fungal abscess despite surgical excision and continued antifungal therapy. Given the high likelihood of poor surgical outcome for repeat debridement and likely need for pelvic evisceration, the patient declined further intervention. She was discharged to hospice with palliative isavuconazole on day +40. She was loaded with 6 doses oral isavuconazole 375mg every 8 hours followed by daily oral isavuconazole 375mg. However, the patient remained clinically stable on isavuconazole, and repeat imaging 4 months...
Mucormycosis is a feared fungal infection often affecting immunocompromised or diabetic patients with high morbidity and mortality. While rhino-cerebro-orbital and pulmonary infections are most frequently encountered, other manifestations may present as our case demonstrates [1]. Described primarily in neonates and infants with gastric infection or necrotizing enterocolitis, gastrointestinal mucormycosis has also been described in adults [9]. It is one of the rarer manifestations, representing only 7–8% of all mucormycosis cases [1,10]. Antemortem diagnosis is made in 25% of cases, and mortality may reach as high as 85% largely due to delay in diagnosis [11].

Clinical manifestations of gastrointestinal mucormycosis are diverse, nonspecific, and range from nausea, vomiting, diarrhea and anorexia to neutropenic fever with obstruction, perforation, peritonitis, sepsis and rapid demise. Mucosal ulceration with hemorrhage is also a well-documented finding along with adjacent demarcated necrosis, edema and vascular thrombosis which is seen on endoscopy or post-operative specimens. Histopathology notes aspae hyphae with angioinvasion, infarction and necrosis [12]. The stomach is most predominately affected followed by the colon and the ileum [13]. Dissemination to liver, pancreas and other organs is possible [14]. Colonic mucormycosis is frequently right-sided, as one case series noted in 8 of 12 colonic infections between 1985 and 2006, and can be confused clinically with typhlitis in the neutropenic patient [12]. Mucorales appendicitis has been described, though we could find only a single other case of fungal diverticulitis in the literature [15,16].

Risk factors for gastrointestinal mucormycosis include immunocompromise, malnutrition and prematurity in neonates, steroid and biologics use for immunosuppression as well as ameboid colitis, typhoid and pellagra [12,14]. Route of entry is assumed to be ingestion or exposure to contaminated material within and outside of the hospital [4,14]. With recent sigmoidoscopy and biopsy in the preceding month, peri-procedural fungal acquisition may have led to the patient’s presentation.

Currently, no blood antigen tests are widely available in order to rapidly detect mucormycosis and few labs keep \textit{Rhizopus arrhizus} primers on hand [4]. Definitive diagnosis requires recovery of fungal elements from histology or culture. Delays in antifungal therapy are associated with increased mortality [2]. Thus, early recognition of gastrointestinal mucormycosis is imperative for optimal outcomes.

High quality evidence regarding optimal antifungal therapy regimens is lacking, though the available ESCMID guidelines recommend combined surgical debridement and liposomal amphotericin B at 5 mg/kg daily [3]. A combined surgical and medical approach is recommended due to the high risk of gut perforation associated with gastrointestinal mucormycosis [4,9,17]. Salvage therapy with oral posaconazole is recommended in refractory disease or amphotericin intolerance [4]. Because our patient had breakthrough mucormycosis while on posaconazole, she was initiated on combination amphotericin B and an echinocandin. Clinical data on combination therapy using an echinocandin is limited. While small retrospective studies and preclinical animal data are supportive of combination therapy, no benefit has been noted in larger, more recent retrospective reviews [18–23]. Despite surgery and combination antifungal therapy, our patient had refractory pelvic mucormycosis and was transitioned to salvage isavuconazole which has thus far controlled her infection.

Our case represents a rare manifestation of gastrointestinal mucormycosis: \textit{Rhizopus arrhizus} diverticulitis resulting in bowel obstruction. Additionally, it supports the use of isavuconazole as salvage therapy for amphotericin-intolerant or refractory infection. Regardless of site of infection, further diagnostic and therapeutic innovations are needed to improve outcomes. In the meantime, improvement in mortality relies on high index of suspicion and early management.

Conflict of interest

The view(s) expressed herein are those of the author(s) and do not reflect the official policy or position of Brooke Army Medical Center, the Department of Defense, the U.S. Air Force, the U.S. Army, the U.S. Air Force Medical Department, the U.S. Army Medical Department, the United States Air Force Office of the Surgeon General, the United States Army Office of the Surgeon General or the U.S. Government.

No conflicts of interest

There are no conflicts of interest for any authors.

Acknowledgements

Thanks to Dr. Bradie N. Bishop, pathologist at Brooke Army Medical Center, who assisted in obtaining histologic images and descriptions.

References

[1] Maureen M. Roden, Theoklis E. Zaoutis, Wendy L. Buchanan, Tena A. Knudsen, Tatyana A. Sarkisova, Robert L. Schuster, Michael Sein, Tin Sein, Christine C. Chiu, Jaclyn H. Chu, Dimitrios P. Kontoyiannis, Thomas J. Walsh. Epidemiology and outcome of zygomycosis: a review of 929 reported cases, Clin. Infect. Dis. 5 (41) (2005) 634–653.
[2] G. Chamilos, R.E. Lewis, D.P. Kontoyiannis, Delaying amphotericin B–based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis, Clin. Infect. Dis. 47 (4) (2008) 503–509.
[3] O.A. Cornely, S. Arikan-Akdagli, E. Dannaoui, et al., ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013, Clin. Microbiol. Infect. 20 (suppl 3) (2014) 5–26.
[4] S.J. Antony, M.S. Parikh, R. Ramirez, B. Applebaum, G. Friedman, J. Do, Gastrointestinal mucormycosis resulting in a catastrophic outcome in an immunocompetent patient, Infect. Dis. Rep. 7 (3) (2015) 6031.
[5] T.J. White, T. Bruns, S. Lee, J. Taylor, Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics, in: M.A. Innis, D.H. Gelfand, J.J. Sninsky, T.J. White (Eds.), PCR Protocols: a Guide to Methods and Applications, Academic Press, San Diego, CA, 1990, pp. 315–322.
[6] A.M. Romanelli, D.A. Sutton, E.H. Thompson, M.G. Rinaldi, B.L. Wickes, Sequence-based identification of filamentous basidiomycetous fungi from clinical specimens: a cautionary note, J. Clin. Microbiol. 48 (3) (2010) 741–752.
[7] C.P. Kurtzman, C.J. Robnett, Identification of clinically important ascomycetous yeasts based on nucleotide divergence in the 5′ end of the large-subunit (26S) ribosomal DNA gene, J. Clin. Microbiol. 35 (5) (1997) 1216–1223.
[8] A. Abe, Y. Oda, K. Asano, T. Sone, Rhizopus delemar is the proper name for Rhizopus oryzae fumaric-malic acid producers, Mycologia 99 (5) (2007) 714–722.
[9] B. Spellberg, Gastrointestinal mucormycosis: an evolving disease, Gastroenterol. Hepatol. 8 (2) (2012) 140–142.
[10] W. Jeong, C. Keighley, R. Wolfe, et al., The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports, Clin. Microbiol. Infect. 25 (1) (2018) 26–34.
[11] M. Martinello, A. Nelson, L. Bignold, D. Shaw, “We are what we eat!” Invasive intestinal mucormycosis: a case report and review of the literature, Med. Mycol. Case Rep. 1 (1) (2012) 52–55.
[12] O.S.-H. Lo, Ileo-colic mucormycosis in adult immunocompromised patients: a surgeon’s perspective, World J. Gastroenterol. 16 (9) (2010) 1165.
[13] B.R. Thomson, P.G. Bade, M. Taams, V. Chrystal, Gastrointestinal mucormycosis, Br. J. Surg. 78 (1991) 952–954.
[14] M. Martinello, A. Nelson, L. Bignold, D. Shaw, “We are what we eat!” Invasive intestinal mucormycosis: a case report and review of the literature, Med. Mycol. Case Rep. 1 (1) (2012) 52–55.
[15] A. Alghamdi, A. Lutynski, M. Minden, C. Rotstein, Successful treatment of gastrointestinal mucormycosis in an adult with acute leukemia: case report and literature review, Curr. Oncol. 24 (1) (2017) 61.
[16] Q. Zhao, X.Y. Han, et al., Toxic megacolon and perforated fungal diverticulitis due to mucor indicus infection in a patient with chronic myelogenous leukemia, Am. J. Clin. Canc. Rev. 1 (2013) 45–50.
[17] A. Alghamdi, A. Lutynski, M. Minden, C. Rotstein, Successful treatment of gastrointestinal mucormycosis in an adult with acute leukemia: case report and literature review, Curr. Oncol. 24 (1) (2017) e61–e64.
[18] A.S. Ibrahim, J.C. Bowman, V. Ayanessian, et al., Caspofungin inhibits Rhizopus oryzae 1,3-β-D-Glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis, Antimicrob. Agents Chemother. 49 (2) (2005) 721–727.
[19] B. Spellberg, Y. Fu, J.E. Edwards, A.S. Ibrahim, Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice, Antimicrob. Agents Chemother. 49 (2) (2005) 830–832.
[20] A.S. Ibrahim, T. Gebremariam, Y. Fu, J.E. Edwards, B. Spellberg, Combination echinocandin-polynye treatment of murine mucormycosis, Antimicrob. Agents Chemother. 52 (4) (2008) 1556–1558.
[21] C. Reed, B. Bryant, A.S. Ibrahim, et al., Combination polynye-caspofungin treatment of rhino-orbital-cerebral mucormycosis, Clin. Infect. Dis. 47 (3) (2008) 364–371.
[22] A. Kyvernitakis, H. Torres, Y. Jiang, G. Chamilos, R. Lewis, D. Kontoyiannis, Initial use of combination treatment does not impact survival of 106 patients with hematologic malignancies and mucormycosis: a propensity score analysis, Clin. Microbiol. Infect. 22 (9) (2016).
[23] M.Z. Abidi, M.R. Sohail, N. Cummins, et al., Stability in the cumulative incidence, severity and mortality of 101 cases of invasive mucormycosis in high-risk patients from 1995 to 2011: a comparison of eras immediately before and after the availability of voriconazole and echinocandin-amphotericin c, Mycoses 57 (11) (2014) 687–698.